JP2004315496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004315496A5 JP2004315496A5 JP2003206492A JP2003206492A JP2004315496A5 JP 2004315496 A5 JP2004315496 A5 JP 2004315496A5 JP 2003206492 A JP2003206492 A JP 2003206492A JP 2003206492 A JP2003206492 A JP 2003206492A JP 2004315496 A5 JP2004315496 A5 JP 2004315496A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- optionally substituted
- compound according
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229940122344 Peptidase inhibitor Drugs 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- VHNILDKAFINLSQ-UHFFFAOYSA-N 1-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]piperazine-2,5-dione Chemical compound NCC=1C(CC(C)C)=NC2=CC=C(N3C(CNC(=O)C3)=O)C=C2C=1C1=CC=C(C)C=C1 VHNILDKAFINLSQ-UHFFFAOYSA-N 0.000 description 1
- OXSMXKYERKHTMN-UHFFFAOYSA-N 4-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]piperazin-2-one Chemical compound NCC=1C(CC(C)C)=NC2=CC=C(N3CC(=O)NCC3)C=C2C=1C1=CC=C(C)C=C1 OXSMXKYERKHTMN-UHFFFAOYSA-N 0.000 description 1
- PEGVEDZUHHLCFU-UHFFFAOYSA-N 5-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]oxypentanoic acid Chemical compound NCC=1C(CC(C)C)=NC2=CC=C(OCCCCC(O)=O)C=C2C=1C1=CC=C(C)C=C1 PEGVEDZUHHLCFU-UHFFFAOYSA-N 0.000 description 1
- 0 CC1=CCc2c(**)c(IN)c(**)nc2CCCCC1 Chemical compound CC1=CCc2c(**)c(IN)c(**)nc2CCCCC1 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003206492A JP4542757B2 (ja) | 2002-08-08 | 2003-08-07 | 縮合複素環化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002231950 | 2002-08-08 | ||
| JP2003051575 | 2003-02-27 | ||
| JP2003206492A JP4542757B2 (ja) | 2002-08-08 | 2003-08-07 | 縮合複素環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004315496A JP2004315496A (ja) | 2004-11-11 |
| JP2004315496A5 true JP2004315496A5 (https=) | 2006-08-17 |
| JP4542757B2 JP4542757B2 (ja) | 2010-09-15 |
Family
ID=33479505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003206492A Expired - Fee Related JP4542757B2 (ja) | 2002-08-08 | 2003-08-07 | 縮合複素環化合物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4542757B2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580526B2 (en) | 2006-04-11 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| JP2006232819A (ja) * | 2005-01-25 | 2006-09-07 | Takeda Chem Ind Ltd | シアノジヒドロピリジン化合物の製造方法 |
| CN101128441A (zh) * | 2005-03-04 | 2008-02-20 | 默克公司 | 具有抗糖尿病活性的稠合芳香化合物 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| AU2011237775A1 (en) | 2010-04-06 | 2012-11-22 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6576644B2 (en) * | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
-
2003
- 2003-08-07 JP JP2003206492A patent/JP4542757B2/ja not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580526B2 (en) | 2006-04-11 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004315496A5 (https=) | ||
| RU2007135339A (ru) | Производные пиридилуксусной кислоты | |
| JP2005112864A5 (https=) | ||
| EP2371811A3 (en) | Azetidinecarboxylic acid derivative and medicinal use thereof | |
| JP2011502958A5 (https=) | ||
| JP2005519908A5 (https=) | ||
| WO2005044192A3 (en) | Triazole compounds and uses related thereto | |
| RU2005114021A (ru) | Производные имидазола и их применение в качестве периферически-селективных ингибиторов дофамин-бета-гидролазы | |
| RU2010126056A (ru) | Органические соединения | |
| JP2002030084A5 (https=) | ||
| WO2001081312A3 (en) | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore | |
| JP2005539088A5 (https=) | ||
| JP2005508923A5 (https=) | ||
| JP2007507494A5 (https=) | ||
| PT2420491E (pt) | Compostos de piperidina 3,5-substituída como inibidores de renina | |
| NO20070088L (no) | 1-, (3R)-amino-4-(2-fluor-fenyl)-butyl !-pyrrolidin-(2R)-karboksylsyre-benzyl amin derivater og beslektede forbindelser som dipeptidyl-peptidase IV (DPP??IV) inhibitorer for behandling av type 2 | |
| EA200501703A1 (ru) | Применение производных азетидинкарбоксамида в терапии | |
| ATE357453T1 (de) | Comt-inhibitoren | |
| JP2004524279A5 (https=) | ||
| JP2008535803A5 (https=) | ||
| MXPA05010020A (es) | Derivados de oxamida. | |
| RU2007116987A (ru) | Новые соединения | |
| WO2004106299A3 (en) | Substituted pyrrole derivatives and their use as hmg-co inhibitors | |
| ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
| JP2005510468A5 (https=) |